Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, which will commence shortly [1] Group 1: Product Development - SHR-2906 injection is a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism, controlling weight, and improving the metabolic environment in the body [1] - The drug is expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, potentially offering clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism and controlling weight [1] Group 1: Product Development - SHR-2906 injection is expected to synergistically reduce energy intake and promote energy expenditure, improving the metabolic environment in the body and potentially offering clinical efficacy in treating overweight and obesity [1] - There are currently no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]